Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant

Ryan H. Senaratne; Joseph D. Mougous; J. Rachel Reader; Spencer J. Williams; Tianjiao Zhang; Carolyn R. Bertozzi; Lee W. Riley

doi:10.1099/jmm.0.46983-0

Volume 56, Issue 4

Research Article

Free

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant

Ryan H. Senaratne¹, Joseph D. Mougous², J. Rachel Reader³, Spencer J. Williams^2,6, Tianjiao Zhang¹, Carolyn R. Bertozzi^2,4,5 and Lee W. Riley¹
View Affiliations Hide Affiliations

Affiliations: ¹ School of Public Health, University of California, Berkeley, CA 94720, USA ² Department of Chemistry, University of California, Berkeley, CA 94720, USA ³ Comparative Pathology Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616, USA ⁴ Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA ⁵ Howard Hughes Medical Institute, University of California, Berkeley, CA 94720, USA
CorrespondenceCarolyn R. Bertozzi  [email protected]  Lee W. Riley  [email protected]

6 FNC1†Present address: School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, Victoria 3010, Australia.
Published: 01 April 2007 https://doi.org/10.1099/jmm.0.46983-0

Abstract

The emergence of drug-resistant Mycobacterium tuberculosis strains and the widespread occurrence of AIDS demand newer and more efficient control of tuberculosis. The protective efficacy of the current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccine is highly variable. Therefore, development of an effective new vaccine has gained momentum in recent years. Recently, several M. tuberculosis mutants were tested as potential vaccine candidates in the mouse model of tuberculosis. However, only some of these mutants were able to generate protection equivalent to that of BCG in mice. This study reports the vaccine potential of an attenuated 5′-adenosine phosphosulfate reductase mutant (ΔcysH) of M. tuberculosis. Immunization of mice with either BCG or ΔcysH followed by infection with the virulent M. tuberculosis Erdman strain demonstrated that ΔcysH can generate protection equivalent to that of the BCG vaccine.

Received: 04/10/2006
Accepted: 21/11/2006
Published Online: 01/04/2007

Keyword(s): BCG, bacille Calmette–Guérin , H&E, haematoxylin and eosin , p.i., post-infection and TB, tuberculosis

SGM

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46983-0

2007-04-01

2024-04-20

Full text loading...

/deliver/fulltext/jmm/56/4/454.html?itemId=/content/journal/jmm/10.1099/jmm.0.46983-0&mimeType=html&fmt=ahah

References

Armbruster C., Junker W., Vetter N., Jaksch G. 1990; Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 162:1216
[Google Scholar]
Besnard M., Sauvion S., Offredo C., Gaudelus J., Gaillard J. L., Veber F., Blanche S. 1993; Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 12:993–997 [CrossRef]
[Google Scholar]
Dye C., Espinal M. A., Watt C. J., Mbiaga C., Williams B. G. 2002a; Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185:1197–1202 [CrossRef]
[Google Scholar]
Dye C., Williams B. G., Espinal M. A., Raviglione M. C. 2002b; Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295:2042–2046 [CrossRef]
[Google Scholar]
Fine P. E. 1995; Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–1345 [CrossRef]
[Google Scholar]
Hondalus M. K., Bardarov S., Russell R., Chan J., Jacobs W. R. Jr, Bloom B. R. 2000; Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis . Infect Immun 68:2888–2898 [CrossRef]
[Google Scholar]
Jackson M., Phalen S. W., Lagranderie M., Ensergueix D., Chavarot P., Marchal G., McMurray D. N., Gicquel B., Guilhot C. 1999; Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun 67:2867–2873
[Google Scholar]
Lugosi L. 1992; Relative persistence capacity of BCG substrains in mouse spleen. Computerized statistical analysis. Multiple comparison. Can J Microbiol 38:165–173 [CrossRef]
[Google Scholar]
Parrish N. M., Dick J. D., Bishai W. R. 1998; Mechanisms of latency in Mycobacterium tuberculosis . Trends Microbiol 6:107–112 [CrossRef]
[Google Scholar]
Pavelka M. S. Jr, Chen B., Kelley C. L., Collins F. M., Jacobs W. R. Jr 2003; Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis . Infect Immun 71:4190–4192 [CrossRef]
[Google Scholar]
Sambandamurthy V. K., Jacobs W. R. Jr 2005; Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7:955–961 [CrossRef]
[Google Scholar]
Sambandamurthy V. K., Wang X., Chen B., Russell R. G., Derrick S., Collins F. M., Morris S. L., Jacobs W. R. Jr 2002; A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8:1171–1174 [CrossRef]
[Google Scholar]
Sambandamurthy V. K., Derrick S. C., Jalapathy K. V., Chen B., Russell R. G., Morris S. L., Jacobs W. R. Jr 2005; Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis . Infect Immun 73:1196–1203 [CrossRef]
[Google Scholar]
Sampson S. L., Dascher C. C., Sambandamurthy V. K., Russell R. G., Jacobs W. R. Jr, Bloom B. R., Hondalus M. K. 2004; Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 72:3031–3037 [CrossRef]
[Google Scholar]
Senaratne R. H., De Silva A. D., Williams S. J., Mougous J. D., Reader J. R., Zhang T., Chan S., Sidders B., Lee D. H. other authors 2006; 5′-Adenosinephosphosulphate reductase (CysH) protects Mycobacterium tuberculosis against free radicals during chronic infection phase in mice. Mol Microbiol 59:1744–1753 [CrossRef]
[Google Scholar]
Smith D. A., Parish T., Stoker N. G., Bancroft G. J. 2001; Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69:1142–1150 [CrossRef]
[Google Scholar]

http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46983-0

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant

J. Med. Microbiol. 56, 454 (2007); https://doi.org/10.1099/jmm.0.46983-0

/content/journal/jmm/10.1099/jmm.0.46983-0

Data & Media loading...

Volume 56, Issue 4

Research Article

Free

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant

Abstract

Most read this month

Most cited Most Cited RSS feed

Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control

Emerging tick-borne pathogens of public health importance: a mini-review

Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children

Pseudomonas aeruginosa – a phenomenon of bacterial resistance

Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens

The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis

The Microbial Ecology of the Large Bowel of Breastfed and Formula-fed Infants During the First Year of Life

Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung

Pseudomonas aeruginosa and microbial keratitis

Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem